Editorial Commentary
Blood tumor mutational burden: are we ready for clinical implementation?
Abstract
Immunotherapy by using antibodies against the immune checkpoint inhibitor (ICI) PD-1 demonstrated objective durable responses in approximately 20% of patients with advanced non-small-cell lung cancer (NSCLC), melanoma, or renal-cell cancer (1).
